Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 128

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 128
---
4 also includes $10,789 of storage revenue recognized in association
with final payment under the legacy contract with the USAMMDA for storing Arakoda purchases. We did not recognize storage revenue for
the three months ended March 31, 2025.

Cash Flows

    For the Three Months Ended March 31,  

    2025  
    2024  
    $ Change  
    % Change 
  
    Net Cash (Used In) Provided By : 

    Operating Activities 
    $(1,597,366) 
    $(1,140,438) 
    $(456,928) 
     40.07%
  
    Investing Activities 
     1,702,518  
     (9,814) 
     1,712,332  
     (17,447.85)
  
    Financing Activities 
     1,696,899  
     1,903,291  
     (206,392) 
     (10.84)
  
    Effect of Foreign Currency Translation on Cash Flow 
     (9,904) 
     (824) 
     (9,080) 
     1,101.94 
  
    Net Increase in Cash and Cash Equivalents 
    $1,792,147  
    $752,215  
    $1,039,932  
     138.25%

31

Cash Used in Operating Activities

Net cash used in operating activities was $1,597,366 for the three
months ended March 31, 2025, as compared to $1,140,438 for the three months ended March 31, 2024. Our net cash used in operating activities
increased, primarily due to higher general and administrative expenses at $1,686,264 for the three months ended March 31, 2025 ($1,075,134
for the three months ended March 31, 2024), as a result of higher sales, advertising and promotion costs and investor outreach expenses,
as discussed above. In addition, we incurred higher research and development costs at $407,622 for the three months ended March 31, 2025
($337,182 for the three months ended March 31, 2024), primarily related to conducting our tafenoquine-babesiosis trial.

Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities